Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 73,955 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 73,955 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $5.69, for a total value of $420,803.95. Following the sale, the insider owned 16,159,744 shares in the company, valued at approximately $91,948,943.36. This trade represents a 0.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Price Performance

Shares of VIR stock opened at $5.66 on Wednesday. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $14.45. The stock’s 50 day simple moving average is $5.00 and its two-hundred day simple moving average is $5.31. The company has a market cap of $786.29 million, a PE ratio of -1.42 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The company had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.38 million. During the same quarter last year, the company earned ($1.02) earnings per share. The company’s revenue for the quarter was down 60.5% on a year-over-year basis. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in Vir Biotechnology during the 2nd quarter worth $35,000. GAMMA Investing LLC increased its holdings in shares of Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after acquiring an additional 5,972 shares during the period. Apollon Wealth Management LLC purchased a new position in shares of Vir Biotechnology in the 2nd quarter valued at $50,000. PNC Financial Services Group Inc. increased its holdings in shares of Vir Biotechnology by 26.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock valued at $68,000 after acquiring an additional 2,171 shares during the period. Finally, FORA Capital LLC purchased a new position in shares of Vir Biotechnology in the 1st quarter valued at $70,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

VIR has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a report on Monday, September 15th. Evercore ISI initiated coverage on Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price target on the stock. Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and increased their price target for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vir Biotechnology in a report on Saturday, September 27th. Finally, Raymond James Financial initiated coverage on Vir Biotechnology in a report on Friday, July 11th. They issued an “outperform” rating on the stock. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).